Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Neoadjuvant Therapy for Pancreatic Cancer
NCT06177522Phase 2Not yet recruiting
- Sponsor
- Jinling Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in pancreatic adenocarcinoma (PDAC), sponsored by Jinling Hospital. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06177522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177522.